Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer

G. Falkson, R. S. Gelman, R. Dreicer, D. C. Tormey, A. S. Alberts, M. A. Coccia-Portugal, D. Rushing, J. M. Bennett

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

One thousand four hundred sixty patients with 2,590 patient-years of follow-up were treated on 15 protocols for metastatic breast cancer with dibromodulcitol (mitolactol; DBD)-containing regimens since 1976. Twenty-three patients developed myelodysplastic syndrome (MDS) and/or acute nonlymphocytic leukemia (ANLL). The overall risk of developing MDS or ANLL per person is 1.6%. In patients who had received more than 16,000 mg of DBD the risk per person is 6%, and in the high-dose subsets of patients who received no prior radiation or alkylator therapy, it is 7.9%. The risk per person increases to a maximum by 30 to 36 months (5.3%). The hgh risk was seen despite a study population of metastatic breast cancer patients with a median survival of 16 months. This analysis strongly suggests that BDB is one of the most potent of the reported leukemogenic-inducing agents. Further use of this drug in both the adjuvant and metastatic situation should be reconsidered.

Original languageEnglish (US)
Pages (from-to)1252-1259
Number of pages8
JournalJournal of Clinical Oncology
Volume7
Issue number9
DOIs
StatePublished - Jan 1 1989

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Falkson, G., Gelman, R. S., Dreicer, R., Tormey, D. C., Alberts, A. S., Coccia-Portugal, M. A., Rushing, D., & Bennett, J. M. (1989). Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer. Journal of Clinical Oncology, 7(9), 1252-1259. https://doi.org/10.1200/JCO.1989.7.9.1252